Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
New Pre-Clinical Data on RGB-286638 Multi-Targeted Kinase Inhibitor Presented at AACR
GPC Biotech to Hold Meeting and Conference Call on March 25, 2009 to Discuss Year-End 2008 Financial Results
Safety and Overall Survival Data in Docetaxel-Refractory Patients Enrolled in the Satraplatin SPARC Trial Being Presented at 2009 ASCO Genitourinary Cancers Symposium
GPC Biotech and Agennix Announce Proposed Merger
GPC Biotech Opens Enrollment in Phase 1 Trial Evaluating RGB-286638 Multi-Targeted Protein Kinase Inhibitor in Patients with Advanced Solid Tumors
GPC Biotech Announces Presentation of New Pre-Clinical Data on RGB-286638 Multi-Targeted Kinase Inhibitor at the American Society of Hematology Annual Meeting
GPC Biotech Reports Financial Results For Third Quarter and First Nine Months of 2008
GPC Biotech Schedules Conference Call on November 13th to Discuss Third Quarter 2008 Financial Results
GPC Biotech to Present at Rodman & Renshaw Annual Global Investment Conference in New York
GPC Biotech Presents New Pre-Clinical Data on RGB-286638 Broad-Spectrum Kinase Inhibitor at EORTC-NCI-AACR Meeting
GPC Biotech Reports Financial Results for Second Quarter and First Six Months of 2008
GPC Biotech Schedules Conference Call on August 13th to Discuss First Half 2008 Financial Results
GPC Biotech Reports that Celgene to Terminate Co-Development and License Agreement for Satraplatin
GPC Biotech Reports That Marketing Authorization Application for Satraplatin is to Be Withdrawn
GPC Biotech To Re-Schedule Annual Shareholders' Meeting
GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial of Satraplatin in Patients with Metastatic Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel
GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes
GPC Biotech to Present at Two Upcoming Conferences: 7th Annual Needham Biotechnology & Medical Technology Conference in New York and Piper Jaffray Europe Conference in London
Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting
New Data from Several Satraplatin Clinical Trials in Solid Tumors Presented at 44th ASCO Annual Meeting
GPC Biotech Announces Data from Several Satraplatin Clinical Trials to be Presented at ASCO Annual Meeting
GPC Biotech Reports Financial Results for First Quarter 2008 - Jun 3 2008 3:16AM
GPC Biotech Schedules Conference Call on May 15th to Discuss First Quarter 2008 Financial Results - Jun 3 2008 3:15AM
GPC Biotech Withdraws Satraplatin NDA Filed for Accelerated Approval
Law Offices of Howard G. Smith Announces Class Action Lawsuit Against GPC Biotech
GPC Biotech AG Named in Purported Class Action Lawsuit in the United States
Abbey Spanier Rodd & Abrams, LLP Commences Class Action Securities Fraud on Behalf of Purchasers of GPC Biotech AG Securities
GPC Biotech to Present at Second Annual Piper Jaffray London Health Care Conference
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
